LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript Summary
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript Summary
Adjusted operating income rose to $64 million, reflecting improved operating leverage, up from $45 million in the same quarter last year. Adjusted operating income margin increased to 20% from 16%.The following is a summary of the LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript:
以下是LivaNova PLC (LIVN) 2024年第三季度業績會議呼叫成績單摘要:
Financial Performance:
金融業績：
LivaNova reported 11% revenue growth in Q3 2024, achieving $318 million, driven by product placements and growth in cardiopulmonary and epilepsy segments.
Adjusted gross margin remained stable at 71%, consistent with the previous year.
Adjusted operating income rose to $64 million, reflecting improved operating leverage, up from $45 million in the same quarter last year. Adjusted operating income margin increased to 20% from 16%.
Full year 2024 revenue guidance was increased to project growth between 8.5% and 9.5% on a constant currency basis.
LivaNova報告2024年第三季度營業收入增長11%，達到31800萬美元，受產品佈局和心肺和癲癇領域增長的推動。
調整後的毛利率保持在71%，與上一年保持一致。
調整後的營業收入上升至6400萬美元，反映了從去年同季度的4500萬美元提高的營運槓桿效應。調整後的營業收入率從16%增加到20%。
2024年全年營業收入指引調整至按恒定貨幣基礎上8.5%至9.5%的增長。
Business Progress:
業務進展：
LivaNova's product Essenz is expected to account for approximately 40% of the annual heart-lung machine unit placements in 2024.
The company is expanding cardiopulmonary manufacturing capacity to meet rising demand, particularly for oxygenators, which saw growth around 15%.
Innovations in the pipeline include advancements in difficult-to-treat depression (DTD) and obstructive sleep apnea (OSA), with pivotal data expected soon that could influence future commercial strategies.
預計LivaNova的產品Essenz將於2024年約佔全年心肺機設備放置的40%。
該公司正在擴大心肺製造業產能，以滿足不斷增長的需求，特別是對氧合器的需求，增長約爲15%。
在研發項目中，包括在難治性抑鬱症（DTD）和阻塞性睡眠呼吸暫停（OSA）方面的創新，關鍵數據預計很快出現，可能影響未來商業策略。
Opportunities:
機會：
Growth driven by cardiopulmonary and epilepsy businesses, supported by pricing strategies and new product launches such as Essenz.
Anticipation of increased procedure penetration and improved reimbursement for the VNS therapy in epilepsy under Medicare, potentially driving broader utilization and market growth.
Pursuing CMS coverage for DTD, which could open additional market opportunities if successful.
心肺療法和癲癇業務推動增長，得到定價策略和Essenz等新產品發佈的支持。
預期心理療法在醫療保險下癲癇症的程序滲透和改善報銷額的增加，可能推動更廣泛的利用和市場增長。
尋求康哲藥業對難治性抑鬱症運作的覆蓋，如果成功，可能開啓額外的市場機會。
Risks:
風險：
The company anticipates a slowdown in epilepsy replacement procedures, which could impact the epilepsy segment's growth rate.
Regulatory outcomes and reimbursement decisions for new treatments in difficult-to-treat depression and obstructive sleep apnea, which are critical for commercial viability.
公司預計癲癇替換手術的放緩可能會影響癲癇業務的增長率。
對於難治性抑鬱症和阻塞性睡眠呼吸暫停症的新治療方法的監管結果和報銷決定對商業可行性至關重要。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
